<?xml version='1.0' encoding='iso-8859-1'?>
<PASBIO>
	<framesest>
		<predicate lemma="lead">
			<roleset id="lead.01" name="resulted&#10;" wordnet="3">
				<roles>
					<role n="0" descr="factors&#10;"/>
					<role n="2" descr="result&#10;"/>
				</roles>
				<example src="EGRAM" no="0">
					<text>By direct sequencing of aberrant SSCA conformators, 15 different mutations were revealed in a total of 18 unrelated families and 13 individual patients. Of these, 10 were novels (7 senseless mutations, 2 mutations leading to frame shift, and 1 predicted mutation affecting normal splicing.</text>
					<arg n="0">7 senseless mutations, 2 mutations</arg>
					<arg n="1">frame shift</arg>
				</example>
				<example src="EGRAM" no="0">
					<text>The direct sequencing of aberrant AECS formers revealed 15 different mutations in a total of 18 unrelated families and 13 individual patients. Of these, 10 were novels (7 mutations without sense, 2 mutations that led to table transfer, and 1 expected mutation that affected normal splicing.</text>
					<arg n="0">7 mutations without sense, 2 mutations</arg>
					<arg n="1">table transfer</arg>
				</example>
				<example src="EGRAM" no="1">
					<text>By direct sequencing of the aberrant SSCA conformators, 15 different mutations were revealed in a total of 18 unrelated families and 13 individual patients. Of these, 10 were novels (7 senseless mutations, 2 mutations led to frame shift, and 1 predicted mutation affecting normal splicing.</text>
					<arg n="0">7 senseless mutations, 2 mutations</arg>
					<arg n="1">frame shift</arg>
				</example>
				<example src="EGRAM" no="1">
					<text>The direct sequencing of the aberrant AECS formers revealed 15 different mutations in a total of 18 unrelated families and 13 individual patients. Of these, 10 were novels (7 mutations without sense, 2 mutations that led to table transfer and 1 expected mutation that affected normal splicing.</text>
					<arg n="0">7 mutations without sense, 2 mutations</arg>
					<arg n="1">table transfer</arg>
				</example>
				<example src="EGRAM" no="2">
					<text>By direct sequencing of aberrant SSCA conformators, 15 different mutations were revealed in a total of 18 unrelated families and 13 individual patients. Of these, 10 were new (7 senseless mutations, 2 mutations leading to frame shift, and 1 predicted mutation affecting normal splicing.</text>
					<arg n="0">7 senseless mutations, 2 mutations</arg>
					<arg n="1">frame shift</arg>
				</example>
				<example src="EGRAM" no="2">
					<text>By direct sequencing of the Aberrant ESA conformators, 15 different mutations were revealed in a total of 18 unrelated families and 13 individual patients. Of these, 10 were new (7 absent mutations, 2 mutations leading to shifting in frames and 1 predicted mutation affecting normal splicing.</text>
					<arg n="0">7 absent mutations, 2 mutations</arg>
					<arg n="1">shifting in frames</arg>
				</example>
				<example src="EGRAM" no="3">
					<text>By direct sequencing of Aberrants, 15 different mutations were revealed in a total of 18 unrelated families and 13 individual patients. Of these, 10 were new (7 absent mutations, 2 mutations led to shifting in frames and 1 predicted mutation affecting normal splicing.</text>
					<arg n="0">7 absent mutations, 2 mutations</arg>
					<arg n="1">shifting in frames</arg>
				</example>
				<example src="EGRAM" no="3">
					<text>By direct sequencing of aberrant SSCA conformators, 15 different mutations were revealed in a total of 18 unrelated families and 13 individual patients. Of these, 10 were new (7 senseless mutations, 2 mutations led to frame shift, and 1 predicted mutation affecting normal splicing.</text>
					<arg n="0">7 senseless mutations, 2 mutations</arg>
					<arg n="1">frame shift</arg>
				</example>
				<example src="EGRAM" no="4">
					<text>closer to the transduction pathway of the putative signal that modulates htrA transcription may lead to the identification of two new genes.</text>
					<arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
					<arg n="1">the identification of two new genes</arg>
				</example>
				<example src="EGRAM" no="4">
					<text>closer to the transduction pathway of the putative signal that modulates the htrA transcription can lead to the identification of two new genes.</text>
					<arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
					<arg n="1">the identification of two new genes</arg>
				</example>
				<example src="EGRAM" no="5">
					<text>The a closer examination of the transduction pathway of putative signals that modulates the transcription htrA leads to the identification of two new genes.</text>
					<arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
					<arg n="1">the identification of two new genes</arg>
				</example>
				<example src="EGRAM" no="5">
					<text>the closest test to the transduction pathway of putative signals that modulates the transcription htrA leads to identification of two new genes.</text>
					<arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
					<arg n="1">identification of two new genes</arg>
				</example>
				<example src="EGRAM" no="6">
					<text>a closer analysis of the putative signal transduction pathway that modulates HtrA transcription led to the identification of two new genes.</text>
					<arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
					<arg n="1">the identification of two new genes</arg>
				</example>
				<example src="EGRAM" no="6">
					<text>The a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription led to the identification of two new genes.</text>
					<arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
					<arg n="1">the identification of two new genes</arg>
				</example>
				<example src="EGRAM" no="7">
					<text>the closest test to the putative signal transduction pathway that modulates the htrA transcription will lead to identification of two new genes.</text>
					<arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
					<arg n="1">identification of two new genes</arg>
				</example>
				<example src="EGRAM" no="7">
					<text>The a closer examination of the transfer pathway of putative signals that modulates the transcription htrA will lead to the identification of two new genes.</text>
					<arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
					<arg n="1">the identification of two new genes</arg>
				</example>
				<example src="EGRAM" no="8">
					<text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D may lead to a 40 to 50-fold synergistic activation of the ANA promoter (figure 3A).</text>
					<arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
					<arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
				</example>
				<example src="EGRAM" no="8">
					<text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D can lead to a synergistic activation of 40 to 50 times that of the ANA promoter (figuration 3A).</text>
					<arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
					<arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
				</example>
				<example src="EGRAM" no="9">
					<text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D led to a synergistic activation of 40 to 50 folds of the promoter ANA (figuration 3A).</text>
					<arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
					<arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
				</example>
				<example src="EGRAM" no="9">
					<text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a 40 to 50-fold synergistic activation of the ANA promoter (figure 3A).</text>
					<arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
					<arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
				</example>
				<example src="EGRAM" no="10">
					<text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D is able to lead a 40 to 50-fold synergistic activation of the aF promoter (picture 3A).</text>
					<arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
					<arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
				</example>
				<example src="EGRAM" no="10">
					<text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D is able to lead to a 40 to 50-fold synergistic activation of the ANA promoter (figure 3A).</text>
					<arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
					<arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
				</example>
				<example src="EGRAM" no="11">
					<text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D led to a synergistic activation of 40 to 50 folds of the promoter ANA (figuration 3A).</text>
					<arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
					<arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
				</example>
				<example src="EGRAM" no="11">
					<text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a 40 to 50-fold synergistic activation of the ANA promoter (figure 3A).</text>
					<arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
					<arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
				</example>
				<example src="EGRAM" no="12">
					<text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D may lead to a 40 to 50-fold synergistic activation of the ANA promoter (figure 3A).</text>
					<arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
					<arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
				</example>
				<example src="EGRAM" no="12">
					<text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D can lead to a synergistic activation of 40 to 50 times that of the ANA promoter (figuration 3A).</text>
					<arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
					<arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
				</example>
				<example src="EGRAM" no="13">
					<text>Crl stimulates sigma (S) activity leads to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
					<arg n="0">Crl stimulates sigma (S) activity</arg>
					<arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
				</example>
				<example src="EGRAM" no="15">
					<text>disorganization of the SNU246 gene in the yeast is lethal and may lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
					<arg n="0">disorganization of the SNU246 gene in the yeast</arg>
					<arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
				</example>
				<example src="EGRAM" no="15">
					<text>Display of the SNU246 gene in yeast is lethal and can lead to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
					<arg n="0">Display of the SNU246 gene in yeast</arg>
					<arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
				</example>
				<example src="EGRAM" no="16">
					<text>disorganization of the SNU246 gene in the yeast was lethal and may lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
					<arg n="0">disorganization of the SNU246 gene in the yeast</arg>
					<arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
				</example>
				<example src="EGRAM" no="16">
					<text>Display of the SNU246 gene in yeast was lethal and could lead to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
					<arg n="0">Display of the SNU246 gene in yeast</arg>
					<arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
				</example>
				<example src="EGRAM" no="17">
					<text>disorganization of the SNU246 gene in the yeast was lethal and led to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
					<arg n="0">disorganization of the SNU246 gene in the yeast</arg>
					<arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
				</example>
				<example src="EGRAM" no="17">
					<text>Display of the SNU246 gene in yeast was lethal and led to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
					<arg n="0">Display of the SNU246 gene in yeast</arg>
					<arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
				</example>
				<example src="EGRAM" no="18">
					<text>disorganization of the SNU246 gene in the yeast was lethal and may lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
					<arg n="0">disorganization of the SNU246 gene in the yeast</arg>
					<arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
				</example>
				<example src="EGRAM" no="18">
					<text>Display of the SNU246 gene in yeast was lethal and could lead to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
					<arg n="0">Display of the SNU246 gene in yeast</arg>
					<arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
				</example>
				<example src="EGRAM" no="19">
					<text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction nCaRE-ref1 could lead to transcriptional suppression C2+e.</text>
					<arg n="0">nCaRE</arg>
				</example>
				<example src="EGRAM" no="19">
					<text>In addition, experiments with an antisense cDNA DNA expression vector introduced into cultivated cells suggested that the A0 interaction (nCaRE)-ref1 ) could lead to transcriptional suppression C2+e.</text>
				</example>
				<example src="EGRAM" no="20">
					<text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction nCaRE-ref1 had led to transcriptional suppression C2+e.</text>
					<arg n="0">nCaRE</arg>
				</example>
				<example src="EGRAM" no="20">
					<text>In addition, experiments with an antisense cDNA DNA expression vector introduced into cultivated cells suggested that the A0 interaction (nCaRE)-ref1 ) had led to transcriptional suppression C2+e.</text>
				</example>
				<example src="EGRAM" no="21">
					<text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction nCaRE-ref1) was able to lead to transcriptional suppression C2+e.</text>
					<arg n="0">nCaRE</arg>
				</example>
				<example src="EGRAM" no="21">
					<text>In addition, experiments with an antisense cDNA DNA expression vector introduced into cultivated cells suggested that the A0 interaction (nCaRE)-ref1) was able to lead to transcriptional suppression C2+e.</text>
				</example>
				<example src="EGRAM" no="22">
					<text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction nCaRE-ref1 is able to lead to transcriptional suppression C2+e-mediated transcriptional supression.</text>
					<arg n="0">nCaRE</arg>
					<arg n="1">C2+e-mediated transcriptional supression</arg>
				</example>
				<example src="EGRAM" no="22">
					<text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction nCaRE-ref1) is able to lead to transcriptional suppression C2+e.</text>
					<arg n="0">nCaRE</arg>
				</example>
				<example src="EGRAM" no="23">
					<text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction DNA (nCaRE)-ref1 leads to C2+ and transcriptional deletion.</text>
					<arg n="0">DNA (nCaRE)-ref1</arg>
					<arg n="1">C2+ and transcriptional deletion</arg>
				</example>
				<example src="EGRAM" no="23">
					<text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction DNA (nCaRE)-ref1  leads to C2+e transcriptional deletion.</text>
					<arg n="0">DNA (nCaRE)-ref1 </arg>
					<arg n="1">C2+e transcriptional deletion</arg>
				</example>
				<example src="EGRAM" no="24">
					<text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
					<arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="24">
					<text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
					<arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="25">
					<text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
					<arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="25">
					<text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was able to lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
					<arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="26">
					<text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
					<arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="26">
					<text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
					<arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="27">
					<text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
					<arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="27">
					<text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
					<arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="28">
					<text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 is able to lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
					<arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="28">
					<text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 is able to lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
					<arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
					<arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
				</example>
				<example src="EGRAM" no="29">
					<text>GM2 genetic deficiency can lead to a neurological disorder, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
					<arg n="0">GM2 genetic deficiency</arg>
					<arg n="1">a neurological disorder</arg>
				</example>
				<example src="EGRAM" no="29">
					<text>genetic deficiency of the GM2 activator can lead to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
					<arg n="0">genetic deficiency of the GM2 activator</arg>
					<arg n="1">a neurological disorder</arg>
				</example>
				<example src="EGRAM" no="30">
					<text>GM2 led to a neurological disease, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
					<arg n="0">GM2</arg>
					<arg n="1">a neurological disease</arg>
				</example>
				<example src="EGRAM" no="30">
					<text>genetic deficiency of the GM2 activator has led in a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
					<arg n="0">genetic deficiency of the GM2 activator</arg>
					<arg n="1">a neurological disorder</arg>
				</example>
				<example src="EGRAM" no="31">
					<text>genetic deficiency of the GM2 activator leading to a neurological disease, an atypical form of Tay-Sachs' disease (gM2 variant AB lymphosidosis).</text>
					<arg n="0">genetic deficiency of the GM2 activator</arg>
					<arg n="1">a neurological disease</arg>
				</example>
				<example src="EGRAM" no="31">
					<text>genetic deficiency of the GM2 activator leading to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
					<arg n="0">genetic deficiency of the GM2 activator</arg>
					<arg n="1">a neurological disorder</arg>
				</example>
				<example src="EGRAM" no="32">
					<text>GM2 led to a neurological disease, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
					<arg n="0">GM2</arg>
					<arg n="1">a neurological disease</arg>
				</example>
				<example src="EGRAM" no="32">
					<text>genetic deficiency of the GM2 activator led to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
					<arg n="0">genetic deficiency of the GM2 activator</arg>
					<arg n="1">a neurological disorder</arg>
				</example>
				<example src="EGRAM" no="33">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite can lead to a 45% expression decrease when cells are grown in a rich environment.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% expression decrease</arg>
				</example>
				<example src="EGRAM" no="33">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite may lead to a 45% decrease in expression when cells are grown in a rich medium.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% decrease in expression</arg>
				</example>
				<example src="EGRAM" no="34">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite led in a 45% decrease in expression when the cells were grown in rich environments.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% decrease in expression</arg>
				</example>
				<example src="EGRAM" no="34">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite led to a 45% decrease in expression when the cells were cultured in a rich medium.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% decrease in expression</arg>
				</example>
				<example src="EGRAM" no="35">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% expression decrease when cells are grown in a rich environment.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% expression decrease</arg>
				</example>
				<example src="EGRAM" no="35">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression when cells are grown in a rich medium.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% decrease in expression</arg>
				</example>
				<example src="EGRAM" no="36">
					<text>growth of scherichia coli in the presence of nitrate or nitrite was able to lead to a 45% drop in expression when the cells were grown in rich environments.</text>
					<arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% drop in expression</arg>
				</example>
				<example src="EGRAM" no="36">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% decrease in expression when the cells were cultured in a rich medium.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% decrease in expression</arg>
				</example>
				<example src="EGRAM" no="37">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite will lead to a 45% decrease in expression when cells are grown in a rich environment.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% decrease in expression</arg>
				</example>
				<example src="EGRAM" no="37">
					<text>growth of Escherichia coli in the presence of nitrate or nitrite will lead to a 45% decrease in expression when the cells are grown in a rich medium.</text>
					<arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
					<arg n="1">a 45% decrease in expression</arg>
				</example>
				<example src="EGRAM" no="38">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, can lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
				</example>
				<example src="EGRAM" no="38">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, may lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
				</example>
				<example src="EGRAM" no="39">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, could lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
				</example>
				<example src="EGRAM" no="39">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, could lead to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
				</example>
				<example src="EGRAM" no="40">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
				</example>
				<example src="EGRAM" no="40">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
				</example>
				<example src="EGRAM" no="41">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, is able to lead to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
				</example>
				<example src="EGRAM" no="41">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, is able to lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
				</example>
				<example src="EGRAM" no="42">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, which led to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
				</example>
				<example src="EGRAM" no="42">
					<text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo (Lin et al., 1997, 1998; Bi et al., 1999).</text>
					<arg n="0">inactivation of the MEF2C gene</arg>
					<arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
				</example>
				<example src="EGRAM" no="43">
					<text>In this homologous part of genes, GPB does not have an exon due to a point mutation at the pulse site of the third intron, which inactivates the pulse event of the 5th and may lead to ligation of the second to the fourth exon.</text>
					<arg n="0">a point mutation at the pulse site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth exon</arg>
				</example>
				<example src="EGRAM" no="43">
					<text>In this homologous part of genes, GPB does not have an exon due to a point mutation at the splicing 5 site of the third intron, which inactivates the splicing 5 event and can lead to ligation of the second to the fourth exon.</text>
					<arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth exon</arg>
				</example>
				<example src="EGRAM" no="44">
					<text>In this homologous part of the genes, GBP does not have an epitome due to a point mutation at the application site of the third intron, which inactivated the 5th cleavage event from splicing and led to ligation of the second to the fourth intron.</text>
					<arg n="0">a point mutation at the application site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth intron</arg>
				</example>
				<example src="EGRAM" no="44">
					<text>In this homologous part of genes, GPB does not have an exon due to a point mutation at the splicing 5 site of the third intron, which inactivated the splicing 5 event and has led to ligation of the second to the fourth exon.</text>
					<arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth exon</arg>
				</example>
				<example src="EGRAM" no="45">
					<text>In this homologous part of the genes, GBP does not have an epitome due to a point mutation at the application site of the third intron, which inactivated the 5th cleavage event from splicing and led to ligation of the second to the fourth intron.</text>
					<arg n="0">a point mutation at the application site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth intron</arg>
				</example>
				<example src="EGRAM" no="45">
					<text>In this homologous part of genes, GPB does not have an exon due to a point mutation at the splicing 5 site of the third intron, which inactivated the splicing 5 event and led to ligation of the second to the fourth exon.</text>
					<arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth exon</arg>
				</example>
				<example src="EGRAM" no="46">
					<text>In this homologous part of genes, GBP lacks an exon due to a point mutation at the application site of the third intron, which inactivates the 5th cleavage event from splicing and will lead to ligation of the second to the fourth exon.</text>
					<arg n="0">a point mutation at the application site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth exon</arg>
				</example>
				<example src="EGRAM" no="46">
					<text>In this homologous part of the genes, GBP does not have an exon due to a point mutation at the pulse site of the third intron, which inactivates the pulse segmentation event and leads to ligation of the second to the fourth intron.</text>
					<arg n="0">a point mutation at the pulse site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth intron</arg>
				</example>
				<example src="EGRAM" no="47">
					<text>In this homologous part of genes, GBP lacks an exon due to a point mutation at the application site of the third intron, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to ligation of the second to the fourth exon.</text>
					<arg n="0">a point mutation at the application site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth exon</arg>
				</example>
				<example src="EGRAM" no="47">
					<text>In this homologous part of the genes, GPB does not have an exon due to a point mutation at the splicing 5 site of the third intron, which inactivates the splicing 5 event and is able to lead to ligation of the second to the fourth exon.</text>
					<arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
					<arg n="1">ligation of the second to the fourth exon</arg>
				</example>
				<example src="EGRAM" no="48">
					<text>Loss of TreR function may lead to derepression of treB coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
					<arg n="0">Loss of TreR function</arg>
					<arg n="1">derepression of treB</arg>
				</example>
				<example src="EGRAM" no="48">
					<text>loss of the TreR function can lead to derepression of the treB encoding an enzyme of the PTS for trehalose and treC, the cytoplasmic trehalose-6-phosphate hydrolasa.</text>
					<arg n="0">loss of the TreR function</arg>
					<arg n="1">derepression of the treB</arg>
				</example>
				<example src="EGRAM" no="49">
					<text>Loss of TreR function led derepression of treB to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
					<arg n="0">Loss of TreR function</arg>
					<arg n="1">derepression of treB</arg>
				</example>
				<example src="EGRAM" no="49">
					<text>loss of the TreR function has led to derepression of treB encoding an enzyititre of PTS for trehalose and TreC, the cytoplasmic trehalose-6-phosphate hydrolasa.</text>
					<arg n="0">loss of the TreR function</arg>
					<arg n="1">derepression of treB</arg>
				</example>
				<example src="EGRAM" no="50">
					<text>Loss of TreR function leads to derepression of treB coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
					<arg n="0">Loss of TreR function</arg>
					<arg n="1">derepression of treB</arg>
				</example>
				<example src="EGRAM" no="50">
					<text>The loss of the TreR function leads to the derepression of the treB encoding an enzyme of the PTS for the trehalose and treC, the cytoplasmic trehalose-6-phosphate hydrolasa.</text>
					<arg n="0">loss of the TreR function</arg>
					<arg n="1">derepression of the treB</arg>
				</example>
				<example src="EGRAM" no="51">
					<text>Loss of TreR function will lead to derepression of treB coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
					<arg n="0">Loss of TreR function</arg>
					<arg n="1">derepression of treB</arg>
				</example>
				<example src="EGRAM" no="51">
					<text>The loss of the TreR function will lead to the derepression of the treB encoding an enzyme of the PTS for the trehalose and treC, the cytoplasmic trehalose-6-phosphate hydrolasa.</text>
					<arg n="0">loss of the TreR function</arg>
					<arg n="1">derepression of the treB</arg>
				</example>
				<example src="EGRAM" no="52">
					<text>Mutations identified include: two frame shifts and a mutation of the splice site leading to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations, two of which involve amino acids within putative transmembrane domains.</text>
					<arg n="0">two frame shifts and a mutation of the splice site</arg>
					<arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
				</example>
				<example src="EGRAM" no="52">
					<text>The identified mutations include: two changes in the picture and one mutation at the ear site leading to A1 (proteins of OA1 vegetated; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids within the transmembrane putative domains.</text>
					<arg n="0">two changes in the picture and one mutation at the ear site</arg>
				</example>
				<example src="EGRAM" no="53">
					<text>The identified mutations include: two frameshifts and a splice site mutation that led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations, two of them involving amino acids located in putative transmembrane domains.</text>
					<arg n="0">two frameshifts and a splice site mutation</arg>
					<arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
				</example>
				<example src="EGRAM" no="53">
					<text>The mutations identified include: two changes in the picture and one mutation at the fitting site that led to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction, two of them involving amino acids within the transmembrane putative domains.</text>
					<arg n="0">two changes in the picture and one mutation at the fitting site</arg>
					<arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
				</example>
				<example src="EGRAM" no="54">
					<text>The identified mutations include: two frameshifts and a splice site mutation leading to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations, two of them involving amino acids located in putative transmembrane domains.</text>
					<arg n="0">two frameshifts and a splice site mutation</arg>
					<arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
				</example>
				<example src="EGRAM" no="54">
					<text>The mutations identified include: with two exchanges of frames and a mutation at the fitting site leading to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids located in putative transmembranous domains.</text>
					<arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
					<arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
				</example>
				<example src="EGRAM" no="55">
					<text>The identified mutations include: two frameshifts and a splice site mutation which led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations, two of them involving amino acids located in putative transmembrane domains.</text>
					<arg n="0">two frameshifts and a splice site mutation</arg>
					<arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
				</example>
				<example src="EGRAM" no="55">
					<text>The mutations identified include: with two exchanges of frames and a mutation at the fitting site that led to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction, two of them involving amino acids located in putative transmembrane domains.</text>
					<arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
					<arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
				</example>
				<example src="EGRAM" no="56">
					<text>The mutation of cut at 5 ends of the intron 5 can lead to the abnormal exon 5 and portion of exon 6 appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
					<arg n="0">mutation of cut at 5 ends of the intron 5</arg>
					<arg n="1">abnormal exon 5 and portion of exon 6</arg>
				</example>
				<example src="EGRAM" no="56">
					<text>the mutation of the splice at 5 ends of the intron 5 can lead to the splice in exon 5 and exon 6 appears to be one of the causes of recessive adreoleukodrophite linked to X.</text>
					<arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
					<arg n="1">the splice in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="57">
					<text>The cut switch at 5 ends of the intron 5 led to the normal exon 5 and portion of exon 6 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
					<arg n="0">cut switch at 5 ends of the intron 5</arg>
					<arg n="1">normal exon 5 and portion of exon 6</arg>
				</example>
				<example src="EGRAM" no="57">
					<text>the mutation of the splice at 5 ends of the intron 5 has led to the abnormal splice in exon 5 and exon 6 appears to be one of the causes of recessive adreoleukodrophite linked to X.</text>
					<arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
					<arg n="1">the abnormal splice in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="58">
					<text>The mutation of cutting at 5 ends of the intron 5 leads to the normal exon 5 and portion of exon 6 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
					<arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
					<arg n="1">normal exon 5 and portion of exon 6</arg>
				</example>
				<example src="EGRAM" no="58">
					<text>the mutation of the splice at 5 ends of the intron 5 leads to the abnormal splice in exon 5 and exon 6 appears to be one of the causes of recessive adreoleukodropia linked to X.</text>
					<arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
					<arg n="1">the abnormal splice in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="59">
					<text>The cut switch at 5 ends of the intron 5 led to the abnormal exon 5 and exon 6 appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
					<arg n="0">cut switch at 5 ends of the intron 5</arg>
					<arg n="1">abnormal exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="59">
					<text>the mutation of the splice at 5 ends of the intron 5 led to the splice in exon 5 and exon 6 appears to be one of the causes of recessive adreoleukodropia linked to X.</text>
					<arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
					<arg n="1">the splice in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="60">
					<text>These data suggest that phosphorylation of MuSK NPXY site may lead to recruitment of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and clustering of AchRs.</text>
					<arg n="0">phosphorylation of MuSK NPXY site</arg>
					<arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
				</example>
				<example src="EGRAM" no="60">
					<text>This data suggests that phosphorylation of the NPXY site of MuSK can lead to recovery of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and AchRs grouping.</text>
					<arg n="0">phosphorylation of the NPXY site of MuSK</arg>
					<arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
				</example>
				<example src="EGRAM" no="61">
					<text>This data suggests that phosphorylation of the site NPXY MuSK led to recovery of a domain protein bound to phosphorosine that works to stimulate phosphorylation and AchRs grouping.</text>
					<arg n="0">phosphorylation of the site NPXY MuSK</arg>
					<arg n="1">recovery of a domain protein bound to phosphorosine</arg>
				</example>
				<example src="EGRAM" no="61">
					<text>This data suggests that phosphorylation of the MuSK site NPXY has led to capture of a protein containing phosphorosine binding domains that works to stimulate phosphorylation and AchRs grouping.</text>
					<arg n="0">phosphorylation of the MuSK site NPXY</arg>
					<arg n="1">capture of a protein containing phosphorosine binding domains</arg>
				</example>
				<example src="EGRAM" no="62">
					<text>This data suggests that phosphorylation of the MuSK site NPXY will lead to capture of a phosphorosine binding protein that works to stimulate phosphorylation and AchRs grouping.</text>
					<arg n="0">phosphorylation of the MuSK site NPXY</arg>
					<arg n="1">capture of a phosphorosine binding protein</arg>
				</example>
				<example src="EGRAM" no="62">
					<text>This data suggests that phosphorylation of the MuSK site NPXY will lead to recovery of a protein bound to phosphorosine that works to stimulate phosphorylation and AchRs grouping.</text>
					<arg n="0">phosphorylation of the MuSK site NPXY</arg>
					<arg n="1">recovery of a protein bound to phosphorosine</arg>
				</example>
				<example src="EGRAM" no="63">
					<text>These data suggest that phosphorylation of MuSK NPXY site led to recruitment of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and clustering of AchRs.</text>
					<arg n="0">phosphorylation of MuSK NPXY site</arg>
					<arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
				</example>
				<example src="EGRAM" no="63">
					<text>This data suggests that phosphorylation of the NPXY site of MuSK led to recovery of a domain protein bound to phosphotyrosine working to stimulate phosphorylation and clustering of AchRs.</text>
					<arg n="0">phosphorylation of the NPXY site of MuSK</arg>
					<arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
				</example>
				<example src="EGRAM" no="64">
					<text>This data suggests that phosphorylation of the site NPXY MuSK was able to lead to recovery of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and clustering of AchRs.</text>
					<arg n="0">phosphorylation of the site NPXY MuSK</arg>
					<arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
				</example>
				<example src="EGRAM" no="64">
					<text>These data suggest that phosphorylation of the NPXY MuSK site was able to lead to recruitment of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and clustering of AchRs.</text>
					<arg n="0">phosphorylation of the NPXY MuSK site</arg>
					<arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
				</example>
				<example src="EGRAM" no="65">
					<text>These results suggest that the different amino acid terminals may lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
					<arg n="0">the different amino acid terminals</arg>
					<arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
				</example>
				<example src="EGRAM" no="65">
					<text>These results suggest that the different amino terminals can lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
					<arg n="0">the different amino terminals</arg>
					<arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
				</example>
				<example src="EGRAM" no="66">
					<text>These results suggest that the distinct termini amino acid is able to lead to the direction of individual VDAC isoforms to different cellular compartments.</text>
					<arg n="0">the distinct termini amino acid</arg>
					<arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
				</example>
				<example src="EGRAM" no="66">
					<text>These results suggest that the different amino acid terminals is able to lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
					<arg n="0">the different amino acid terminals</arg>
					<arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
				</example>
				<example src="EGRAM" no="67">
					<text>These results suggest that the different amino terminals can lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
					<arg n="0">the different amino terminals</arg>
					<arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
				</example>
				<example src="EGRAM" no="67">
					<text>These results suggest that the different amino acid terminals may lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
					<arg n="0">the different amino acid terminals</arg>
					<arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
				</example>
				<example src="EGRAM" no="68">
					<text>These results suggested that the different amino terminals has led in the orientation of individual VDAC isoforms to different cellular compartments.</text>
					<arg n="0">the different amino terminals</arg>
					<arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
				</example>
				<example src="EGRAM" no="68">
					<text>These results suggest that the distinct termini amino acid led to the direction of individual VDAC isoforms to different cellular compartments.</text>
					<arg n="0">the distinct termini amino acid</arg>
					<arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
				</example>
				<example src="EGRAM" no="69">
					<text>This basic pair G:C is also the strongest determinant in sequence selection experience leading to BRE identification (Lagrange et al., 1998).</text>
					<arg n="0">sequence selection experience</arg>
					<arg n="1">BRE identification</arg>
				</example>
				<example src="EGRAM" no="69">
					<text>This base pair G:C is also the strongest determinant in the sequence selection experiment leading to the identification of BRE (Lagrange et al., 1998).</text>
					<arg n="0">the sequence selection experiment</arg>
					<arg n="1">the identification of BRE</arg>
				</example>
				<example src="EGRAM" no="70">
					<text>This basic pair G:C is also the strongest determinant in sequence selection experience that leads to BRE identification (Lagrange et al., 1998).</text>
					<arg n="0">sequence selection experience</arg>
					<arg n="1">BRE identification</arg>
				</example>
				<example src="EGRAM" no="70">
					<text>This base pair G:C is also the strongest determinant in the sequence selection experiment leads to the identification of BRE (Lagrange et al., 1998).</text>
					<arg n="0">the sequence selection experiment</arg>
					<arg n="1">the identification of BRE</arg>
				</example>
				<example src="EGRAM" no="71">
					<text>This basic pair G:C is also the strongest determinant in sequence selection experience that led to BRE identification (Lagrange et al., 1998).</text>
					<arg n="0">sequence selection experience</arg>
					<arg n="1">BRE identification</arg>
				</example>
				<example src="EGRAM" no="71">
					<text>This base pair G:C is also the strongest determinant in the sequence selection experiment that has led to the identification of BRE (Lagrange et al., 1998).</text>
					<arg n="0">the sequence selection experiment</arg>
					<arg n="1">the identification of BRE</arg>
				</example>
				<example src="EGRAM" no="72">
					<text>This basic pair G:C is also the strongest determinant in sequence selection experience that leads to BRE identification (Lagrange et al., 1998).</text>
					<arg n="0">sequence selection experience</arg>
					<arg n="1">BRE identification</arg>
				</example>
				<example src="EGRAM" no="72">
					<text>This base pair G:C is also the strongest determinant in the sequence selection experiment leads to the identification of BRE (Lagrange et al., 1998).</text>
					<arg n="0">the sequence selection experiment</arg>
					<arg n="1">the identification of BRE</arg>
				</example>
				<example src="EGRAM" no="73">
					<text>This basic pair G:C is also the strongest determinant in sequence selection experience that led to BRE identification (Lagrange et al., 1998).</text>
					<arg n="0">sequence selection experience</arg>
					<arg n="1">BRE identification</arg>
				</example>
				<example src="EGRAM" no="73">
					<text>This base pair G:C is also the strongest determinant in the sequence selection experiment that led to the identification of BRE (Lagrange et al., 1998).</text>
					<arg n="0">the sequence selection experiment</arg>
					<arg n="1">the identification of BRE</arg>
				</example>
				<example src="EGRAM" no="74">
					<text>This can lead to a wide diversity of nebulae and nebulae.</text>
					<arg n="0">This</arg>
					<arg n="1">a wide diversity of nebulae and nebulae</arg>
				</example>
				<example src="EGRAM" no="74">
					<text>this  can lead to a substantial diversity of isoforms of nebulin and nebulae.</text>
					<arg n="0">this </arg>
					<arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
				</example>
				<example src="EGRAM" no="75">
					<text>This led to a wide diversity of nebulin and nebule isoforms.</text>
					<arg n="0">This</arg>
					<arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
				</example>
				<example src="EGRAM" no="75">
					<text>this  has led in a substantial diversity of isoforms of nebulin and nebulae.</text>
					<arg n="0">this </arg>
					<arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
				</example>
				<example src="EGRAM" no="76">
					<text>this  leading to a substantial diversity of isoforms of nebulin and nebulette.</text>
					<arg n="0">this </arg>
					<arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
				</example>
				<example src="EGRAM" no="76">
					<text>This is leading to a wide diversity of nebulin and nebule isoforms.</text>
					<arg n="0">This</arg>
					<arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
				</example>
				<example src="EGRAM" no="77">
					<text>This may lead to a wide diversity of nebulins and nebule isoforms.</text>
					<arg n="0">This</arg>
					<arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
				</example>
				<example src="EGRAM" no="77">
					<text>this  can lead to a substantial diversity of isoforms of nebulin and nebulae.</text>
					<arg n="0">this </arg>
					<arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
				</example>
				<example src="EGRAM" no="78">
					<text>This patient DNA contains a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactive frame shift in the protein's terminal C.</text>
					<arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
					<arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the protein's terminal C</arg>
				</example>
				<example src="EGRAM" no="78">
					<text>This patient's DNA contains a C---A transversion following the helix of the last intron of the ERCC-3 allele leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
					<arg n="0">a C---A transversion following the helix of the last intron of the ERCC-3 allele</arg>
				</example>
				<example src="EGRAM" no="79">
					<text>This DNA of patients contains a C--A transversion after the last intron sternalization aceptors of the ERCC-3 allele that can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the protein's C-termoid.</text>
					<arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
					<arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the protein's C-termoid</arg>
				</example>
				<example src="EGRAM" no="79">
					<text>This patient DNA contains a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele that can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the protein's terminal C.</text>
					<arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
					<arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the protein's terminal C</arg>
				</example>
				<example src="EGRAM" no="80">
					<text>This patient DNA contains a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele which leads to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
					<arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
					<arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
				</example>
				<example src="EGRAM" no="80">
					<text>This patient DNA contains a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the protein's terminal C.</text>
					<arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
					<arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the protein's terminal C</arg>
				</example>
				<example src="EGRAM" no="81">
					<text>ledTledhlediledsled ledDledNledAled ledoledfled ledpledaledtlediledelednledtledsled ledcledolednledtledaledilednledsled ledaled ledCled-led-ledAled ledtledrledalednledsledvledeledrledslediledolednled ledaledfledtledeledrled ledtledhledeled ledsledtledeledrlednleduledtled ledaledcledeledpledtledoledrled ledoledfled ledtledhledeled ledlledaledsledtled ledilednledtledrledolednled ledoledfled ledtledhledeled ledEledRledCledCled-led3led ledaledlledlledeledlledeled ledtledhledaledtled ledlledeleddled ledtledoled ledalednled ledilednledsledeledrledtlediledolednled ledoledfled led4led ledbledpled ledilednledtledoled ledmledRledNledAled ledalednleddled ledalednled ledilednledaledcledtlediledvledaledtledilednledgled ledfledrledaledmledeled ledsledhlediledfledtled ledilednled ledtledhledeled ledpledrledoledtledeledilednled'ledsled ledCled-ledtledeledrledmledoledileddled.led</text>
					<arg n="0">a C--A transversion after the sternut aceptor of the last intron of the ERCC-3 allele that led to A1 (an insertion of 4 bp into mRNA and an inactivating frame shift in the protein's C-termoid)</arg>
					<arg n="1">an insertion of 4 bp into mRNA and an inactivating frame shift in the protein's C-termoid</arg>
				</example>
				<example src="EGRAM" no="81">
					<text>This DNA of patients contains a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele that led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the protein's terminal C.</text>
					<arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
					<arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the protein's terminal C</arg>
				</example>
				<example src="EGRAM" no="82">
					<text>the 5-end mutation of the intron 5 may have led to abnormal portion in exon 5 and exon 6 and resulted in unstable and abnormal ALD proteins; lignocceryl CoA ligase could not transport very long-chain fatty acids (VLCFA) to the peroxisome and could not function normally; consequently, the defective beta oxidation of VLCFA in the peroxisome co</text>
					<arg n="0">the 5-end mutation of the intron 5</arg>
					<arg n="1">abnormal portion in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="82">
					<text>this mutation at 5 ends of the intron 5 could have led to abnormal portion in exon 5 and exon 6 and resulted in unstable and abnormal ALD proteins; lignocceryl CoA ligase could not carry very long-chain fatty acids (VLCFA) to peroxisome and could not function normally; consequently, defective beta oxidation of VLCFA in peroxisome could result in accumulation of VLCFAS in the central nervous system, adrenal glands and blood.</text>
					<arg n="0">this mutation at 5 ends of the intron 5</arg>
					<arg n="1">abnormal portion in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="83">
					<text>the 5-end mutation of the intron 5 may leading in abnormal portion in exon 5 and exon 6 and cause unstable and abnormal ALD proteins; lignocceryl CoA ligase does not carry very long-chain fatty acids (VLCFA) to the peroxisome and does not work normally; consequently, the defective beta oxidation of VLCFA in the peroxisome may leading in</text>
					<arg n="0">the 5-end mutation of the intron 5</arg>
					<arg n="1">abnormal portion in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="83">
					<text>this mutation at 5 ends of the intron 5 can leading in abnormal portion in exon 5 and exon 6 and cause unstable and abnormal ALD proteins; lignocceryl CoA ligase could not transport very long-chain fatty acids (VLCFA) to peroxisome and could not function normally; consequently, defective beta oxidation of VLCFA in peroxisome could leading in accumulation of VLCFAS in the central nervous system, adrenal glands and blood.</text>
					<arg n="0">this mutation at 5 ends of the intron 5</arg>
					<arg n="1">abnormal portion in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="84">
					<text>the 5-end mutation of the intron 5 may led to abnormal portion in exon 5 and exon 6 and cause unstable and abnormal ALD proteins; lignocceryl CoA ligase does not carry very long-chain fatty acids (VLCFA) to the peroxide and does not work normally; consequently, the beta-defective oxidation of VLCFA in the peroxide may result in a</text>
					<arg n="0">the 5-end mutation of the intron 5</arg>
					<arg n="1">abnormal portion in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="84">
					<text>this mutation at 5 ends of the intron 5 can led to abnormal portion in exon 5 and exon 6 and cause unstable and abnormal ALD proteins; lignocceryl CoA ligase cannot transport very long-chain fatty acids (VLCFA) to the peroxysoma and cannot function normally; consequently, the defective beta oxidation of VLCFA in the peroxysoma can result in an accumulation of VLCFAS in the central nervous system, adrenal glands and blood.</text>
					<arg n="0">this mutation at 5 ends of the intron 5</arg>
					<arg n="1">abnormal portion in exon 5 and exon 6</arg>
				</example>
				<example src="EGRAM" no="86">
					<text>This was caused by a mutation point (GTC---ATC) in codon 383 which leading to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
					<arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
					<arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
				</example>
				<example src="EGRAM" no="86">
					<text>This was caused by a punctual mutation (GTC----ATC) in codon 383 leading to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
					<arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
					<arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
				</example>
				<example src="EGRAM" no="87">
					<text>This was caused by a point mutation (GTC---ATC) in codon 383 leads to conservative substitution of isoleucine for valine in the transporter's fifth extracellular putative loop.</text>
					<arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
					<arg n="1">conservative substitution of isoleucine for valine in the transporter's fifth extracellular putative loop</arg>
				</example>
				<example src="EGRAM" no="87">
					<text>This was caused by a punctual mutation (GTC----ATC) in codon 383 that leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
					<arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
					<arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
				</example>
				<example src="EGRAM" no="88">
					<text>This was caused by a mutation point (GTC---ATC) in codon 383 which led to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
					<arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
					<arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
				</example>
				<example src="EGRAM" no="88">
					<text>This was caused by a punctual mutation (GTC----ATC) in codon 383 that led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
					<arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
					<arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
				</example>
				<example src="EGRAM" no="89">
					<text>This was caused by a point mutation (GTC---ATC) in codon 383 that can lead to conservative substitution of isoleucine for valine in the transporter's fifth extracellular putative loop.</text>
					<arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
					<arg n="1">conservative substitution of isoleucine for valine in the transporter's fifth extracellular putative loop</arg>
				</example>
				<example src="EGRAM" no="89">
					<text>This was caused by a punctual mutation (GTC----ATC) in codon 383 that may lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
					<arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
					<arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
				</example>
				<example src="EGRAM" no="90">
					<text>This was caused by a mutation point (GTC---ATC) in codon 383 which has led to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
					<arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
					<arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
				</example>
				<example src="EGRAM" no="90">
					<text>This was caused by a punctual mutation (GTC----ATC) in codon 383 that led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
					<arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
					<arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
				</example>
				<example src="EGRAM" no="91">
					<text>A0 (i.e., in turn, led to synergistic activation of ANA and other target promoters of MEF2 regardless of the binding activity of meF2.</text>
					<arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
				</example>
				<example src="EGRAM" no="91">
					<text>A0, in turn, led synergic activation of the ANA and other MEF2 target promoters to an activity independent of the MEF2 DNA binding activity.</text>
					<arg n="1">synergic activation of the ANA and other MEF2 target promoters</arg>
				</example>
				<example src="EGRAM" no="92">
					<text>A0, in turn, is capable of leading to synergic activation of the ANF and other MEF2 target promoters regardless of the DNA binding activity of MEF2.</text>
					<arg n="1">synergic activation of the ANF and other MEF2 target promoters</arg>
				</example>
				<example src="EGRAM" no="92">
					<text>A0, in turn, is able to lead to synergistic activation of ANA and other target MEF2 promoters regardless of the DNA binding activity of MEF2.</text>
					<arg n="1">synergistic activation of ANA and other target MEF2 promoters</arg>
				</example>
				<example src="EGRAM" no="93">
					<text>This, in turn, is leading to synergistic activation of ANA and other target promoters of MEF2 regardless of the DNA binding activity of MEF2.</text>
					<arg n="0">This</arg>
					<arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
				</example>
				<example src="EGRAM" no="93">
					<text>A0 (This, in turn, leading to synergic activation of the ANA and other target promoters of MEF2 regardless of the DNA binding activity of MEF2.</text>
					<arg n="1">synergic activation of the ANA and other target promoters of MEF2</arg>
				</example>
				<example src="EGRAM" no="94">
					<text>A0, in turn, led to synergic activation of the ANF and other MEF2 target promoters regardless of MEF2's DNA binding activity.</text>
					<arg n="1">synergic activation of the ANF and other MEF2 target promoters</arg>
				</example>
				<example src="EGRAM" no="94">
					<text>A0, in turn, led to synergistic activation of ANA and other target promoters of MEF2 regardless of the DNA binding activity of MEF2.</text>
					<arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
				</example>
				<example src="EGRAM" no="95">
					<text>A0 (i. e., in turn, will lead to synergistic activation of ANA and other target promoters of MEF2 regardless of the meF2 DNA binding activity.</text>
					<arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
				</example>
				<example src="EGRAM" no="95">
					<text>A0, in turn, will lead to synergic activation of the ANA and other target promoters of MEF2 regardless of the DNA binding activity of MEF2.</text>
					<arg n="1">synergic activation of the ANA and other target promoters of MEF2</arg>
				</example>
				<example src="EGRAM" no="96">
					<text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to loss of FOm.</text>
					<arg n="0">loss of FOm</arg>
				</example>
				<example src="EGRAM" no="96">
					<text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to loss of OmpF.</text>
					<arg n="0">loss of OmpF</arg>
				</example>
				<example src="EGRAM" no="97">
					<text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to loss of FOm.</text>
					<arg n="0">loss of FOm</arg>
				</example>
				<example src="EGRAM" no="97">
					<text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to loss of OmpF.</text>
					<arg n="0">loss of OmpF</arg>
				</example>
				<example src="EGRAM" no="98">
					<text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to loss of FOm.</text>
					<arg n="0">loss of FOm</arg>
				</example>
				<example src="EGRAM" no="98">
					<text>The transduction of the MarA region from a sea strain, but not from a wild strain, is able to lead to the loss of OmpF.</text>
					<arg n="0">the loss of OmpF</arg>
				</example>
				<example src="EGRAM" no="99">
					<text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to loss of FOm.</text>
					<arg n="0">loss of FOm</arg>
				</example>
				<example src="EGRAM" no="99">
					<text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to loss of OmpF.</text>
					<arg n="0">loss of OmpF</arg>
				</example>
				<example src="EGRAM" no="100">
					<text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to loss of FOm.</text>
					<arg n="0">loss of FOm</arg>
				</example>
				<example src="EGRAM" no="100">
					<text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to loss of OmpF.</text>
					<arg n="0">loss of OmpF</arg>
				</example>
				<example src="EGRAM" no="101">
					<text>We also study in detail a complex mutation of the coupling site, 3332dupl8bp, which leads to an abnormal JNA, resulting in a premature arrest codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
				</example>
				<example src="EGRAM" no="101">
					<text>We also studied in detail the a complex mutation of the coupling site, the 3332dupl8bp, which leads to the an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
				</example>
				<example src="EGRAM" no="102">
					<text>We also studied in detail the a complex mutation of the coupling site, the 3332dupl8bp, which led to the an altered JNA, resulting in a premature arrest codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
				</example>
				<example src="EGRAM" no="102">
					<text>We also studied in detail the a complex mutation of the coupling site, the 3332dupl8bp, which led to the an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
				</example>
				<example src="EGRAM" no="103">
					<text>We also studied in detail a complex coupling site mutation, 3332dupl8bp, which was found to lead to an altered ARNJ1 resulting in a premature stop codon.</text>
					<arg n="0">a complex coupling site mutation</arg>
					<arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
				</example>
				<example src="EGRAM" no="103">
					<text>We also studied in detail the a complex mutation of the coupling site, the 3332dupl8bp, which was found to lead to the an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
				</example>
				<example src="EGRAM" no="104">
					<text>We also study in detail a complex mutation of the coupling site, 3332dupl8bp, which leading to an abnormal JNA, resulting in a premature arrest codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
				</example>
				<example src="EGRAM" no="104">
					<text>We also studied in detail the a complex mutation of the coupling site, the 3332dupl8bp, which leading to the an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
				</example>
				<example src="EGRAM" no="105">
					<text>We also study in detail a complex mutation of the coupling site, 3332dupl8bp, which is thought to lead to an abnormal JNA, resulting in a premature arrest codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
				</example>
				<example src="EGRAM" no="105">
					<text>We also study in detail a complex mutation of the coupling site, 3332dupl8bp, which is thought to lead to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
					<arg n="0">a complex mutation of the coupling site</arg>
					<arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
				</example>
				<example src="EGRAM" no="106">
					<text>an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase is led by Crl stimulates sigma activity (S).</text>
					<arg n="0">Crl stimulates sigma activity (S)</arg>
					<arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
				</example>
				<example src="EGRAM" no="106">
					<text>an increase in the rate of transcription of a subset of rpoS genes in the stationary phase is led to Crl stimulates sigma activity (S).</text>
					<arg n="0">Crl stimulates sigma activity (S)</arg>
					<arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
				</example>
				<example src="EGRAM" no="107">
					<text>an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase was led by Crl stimulates sigma activity (S).</text>
					<arg n="0">Crl stimulates sigma activity (S)</arg>
					<arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
				</example>
				<example src="EGRAM" no="107">
					<text>an increase in the transcription rate of a subset of rpoS genes in the stationary phase was led to Crl stimulates sigma activity (S).</text>
					<arg n="0">Crl stimulates sigma activity (S)</arg>
					<arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
				</example>
			</roleset>
		</predicate>
	</framesest>
</PASBIO>